CredenceResearch Logo

Drug lifecycle assessment

Compare lifecycle options while there is still time to fund them before exclusivity ends

Lifecycle options such as new indications, formulations or markets take years to develop, so the decision to fund them often comes long before generic or biosimilar competition arrives. Credence Research compares lifecycle options on market value, feasibility and competitive timing, and estimates the commercial effect of loss of exclusivity.

Discuss your lifecycle questionSee what the outputs include

A drug's commercial lifecycle, and where evidence is usually thinnest

1Patent filing and developmentEffective exclusivity period
2Approval and launchUptake against forecast
3Growth and peakValue of the next indication
4Exclusivity expiryChallenger timing
5Generic or biosimilar entryRate of price and share erosion

Marked items usually need expert input, analog analysis or scenario modeling. Patent status should be confirmed by qualified counsel.

What is drug lifecycle assessment?

Drug lifecycle assessment evaluates options for sustaining a drug's commercial value over time, such as new indications, patient groups, formulations, combinations and markets, and estimates how revenue is likely to change when exclusivity ends. It is commercial research, not a legal opinion on patents or exclusivity.

Decisions that call for a lifecycle assessment

These decisions typically arise several years before loss of exclusivity, when options can still be developed in time.

Choosing the next indication

Several indications are possible, and you can fund only some trials.

Evaluating a new formulation or delivery form

You need to know whether prescribers and payers would value it enough to justify development.

Expanding into new markets

You need to compare countries where the drug is not yet available.

Planning for loss of exclusivity

You need realistic scenarios for price and share erosion after generic or biosimilar entry.

Reviewing a mature portfolio

You need to decide which brands to invest in, maintain or divest.

Start with what you already know

Most teams know their brand's sales history, patent estate and development options. What usually remains uncertain is how much each option is worth in the market, how prescribers and payers would respond, and how quickly competitors will enter.

Questions a lifecycle assessment can investigate

Options

  • Which new indications or patient groups have the largest unmet need?
  • Would a new formulation change prescribing or adherence?
  • Which markets offer the best return for expansion?

Value

  • What revenue could each option add, and when?
  • How would payers price or restrict it?
  • What evidence would each option require?

Competition

  • When are generic or biosimilar challengers likely to enter?
  • How quickly have prices and share fallen for comparable products?
  • How are competitors extending their own lifecycles?

Portfolio

  • Which lifecycle options should be funded first?
  • How do options compare on value, risk and timing?
  • What happens to revenue if no action is taken?

What public sources can tell you, and what needs further validation

Patent listings, exclusivity records, trial registries and published erosion studies describe much of the context. They leave important commercial questions open.

Where desk research is often sufficient, and where decisions usually need more evidence
TopicDesk research can often establishWhat often remains unresolvedHow it can be tested
Exclusivity timingListed patents and regulatory exclusivitiesEffective date after challenges and settlementsScenario ranges; legal status confirmed by counsel
Challenger entryFiled applications where publicWho will launch, when and how manyExpert interviews and analog analysis
Price and share erosionPublished studies for past productsErosion for your product in your marketsAnalog analysis and scenario modeling
Value of new indicationsPrevalence and trial landscapeTreated patients, positioning and payer responseClinician and payer interviews and patient-based forecasting
Formulation valueCompetitor formulationsWhether prescribers and payers would pay for the changePrescriber and payer research

AI tools can speed up the review of patent listings, trial registries and published erosion studies. Estimates of challenger timing and the value of a lifecycle option depend on assumptions that should be tested with experts and stated openly.

How evidence gaps translate into research

This example is illustrative. It shows how a study could be designed and does not describe a specific client engagement.

Choosing between two new indications

Illustrative example
Business question
A company must decide which of two additional indications to pursue for a marketed specialty drug.
Evidence gap
Both indications have published prevalence data, but treated patient numbers, competitor timing and payer attitudes differ and are unclear.
Research method
Patient-based forecasts for each indication, interviews with clinicians and payers, and competitive landscape analysis.
Deliverable
A side-by-side comparison of the two options on value, timing, evidence requirements and risk.
Decision supported
Which indication to fund and what trial design would best support access.

Our research approach

We gather input from market stakeholders and specialists across functions, including marketing, research and development, manufacturing and regulatory, and combine it with published evidence.

Methods, what they are used for and their limits
MethodPurposeLimitation
Exclusivity and landscape reviewMap patents, exclusivities and competitor activityNot a legal opinion
Analog analysisEstimate erosion and uptake from comparable productsNo analog matches exactly
Clinician and payer interviewsTest the value of new indications and formulationsIndividual views; cross-checked
Patient-based forecastingEstimate revenue from each optionShown as ranges
Scenario analysisCompare outcomes under different entry and pricing assumptionsScenarios are not predictions

We do not provide legal opinions on patents or exclusivity, and we do not seek confidential information about competitors.

What you receive

Deliverables depend on scope, and not every study includes every output. We agree on outputs during scoping.

  • Lifecycle option comparison

    Options compared on value, timing, evidence needs and risk.

    Use it to decide which options to fund.

  • Loss-of-exclusivity scenarios

    Revenue under different challenger entry and erosion assumptions.

    Use it to plan budgets and responses.

  • Indication or market forecasts

    Patient-based revenue estimates for each option.

    Use it to size each opportunity.

  • Competitive lifecycle review

    How competitors and challengers are positioning, with evidence dates.

    Use it to anticipate market changes.

Published report or custom research?

Published pharmaceutical market reports can describe the treatment landscape and market size. A lifecycle assessment is more useful when you must choose among specific options for a specific brand.

Is a lifecycle assessment right for your decision?

  • You have a marketed or late-stage drug with lifecycle options to compare.
  • Loss of exclusivity is expected within your planning horizon.
  • Option values depend on assumptions you cannot yet support.
  • You have a portfolio or budget decision ahead.

If most of these apply, a scoping conversation is likely to be productive. If not, a published report or a short discussion about scope may be a better first step.

Discuss your lifecycle question

Frequently asked questions

Discuss your lifecycle question

Tell us about the brand, the options you are considering and your timeline.

What happens next

A member of our research team reviews your brief and contacts you to discuss scope and approach. If existing research can answer your question, we will point you to it.

Phone